antibodies: rituximab (Rituxan®) especially for disease relapse. Belimumab (Benlysta®) is under investigation.

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor, also known as B-lymphocyte stimulator. It is approved in the United States, Canada, and the European Union to treat systemic lupus erythematosus